Cholera rapid diagnostic tests at the host-microbe interface: Key Considerations for Global Deployments

Authors

S. M. Ahmed[1*†], Md. Abu Sayeed[2†], I. Sriguha[2], E. T. Cato[2], A. Creasy-Marrazzo[2], K. Islam[3], Md. I.UL. Khabir[3,4], Md. T. R. Bhuiyan[3], Y. Begum[3], Md. Taufiqul Islam[3], Zahid Hasan Khan[3], E. Freeman[2], A. Vustepalli[2], L. Brinkley[2], M. Kamat[5], L. S. Bailey[5], N. Madi[6,7], F. Qadri[3], B. J. Shapiro[6,7], D. T. Leung[9], K. B. Basso[5], D. A. Sack[8], J. R. Andrews[10], A. I. Khan[3*], E. J. Nelson[2*]

Affiliations

[1] Department of Epidemiology, Emory University, Atlanta, GA, USA
[2] Departments of Pediatrics and Environmental and Global Health, University of Florida, Gainesville, FL, USA
[3] Infectious Diseases Division, International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh
[4] Alabama State University, Montgomery, AL, USA
[5] Department of Chemistry, University of Florida, Gainesville, FL, USA
[6] Department of Microbiology & Immunology, McGill University, Montréal, Canada
[7] McGill Centre for Microbiome Research, McGill University, Montréal, Canada
[8] Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
[9] Department of Internal Medicine, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, Utah, USA
[10] Division of Infectious Diseases and Geographic Medicine, School of Medicine, Stanford University, Stanford, California

[†] Co-first authorship
[*] Corresponding authors

Email: sharia.m.ahmed@emory.edu, ashrafk@icddrb.org; eric.nelson@ufl.edu

Keywords

Cholera; diarrhoea; diarrhea, *Vibrio cholerae*; bacteriophage; phage; antibiotics; antimicrobial resistance; AMR; rapid diagnostic test; RDT; Bangladesh; outbreak

ABSTRACT

Background. Effective cholera outbreak response requires accurate bedside rapid diagnostic tests (RDTs) because access to laboratories is often limited. Formative studies suggest cholera diagnostics have multiple vulnerabilities, including antibiotics and predation by bacteriophage ('phage') specific to *Vibrio cholerae* (*Vc*).

Methods. We conducted a prospective nationwide study in Bangladesh among over 2000 patients with diarrhoeal disease to characterize how these vulnerabilities impact RDT performance. Assays included culture, qPCR and mass spectrometry.

Findings. With the current gold standard of culture or qPCR *Vc* positivity, we found no effect of phage on RDT performance. When the diagnostic criteria were expanded to include phage, there was a small decrease in RDT sensitivity. In contrast, large increases in sensitivity and specificity were observed among patients with moderate and severe dehydration. Using the expanded definition, the odds of RDT positivity decreased among cholera patients with phage exposure. The effect was most robust among patients with severe dehydration. Antibiotic were detected in over 80% of samples by LC-MS/MS which limited testing for effects on RDTs. Applying these findings, we estimated that restricting RDT use to severe patients with no reported antibiotic exposure increases sensitivity by 50% compared to unrestricted use. If phage were a diagnostic proxy for *Vc*, we estimate RDT would miss an additional 17% of cholera cases.

Interpretation. Cholera RDTs have critical limitations that require consideration in global deployments. Inclusion of phage detection in diagnostic criteria may improve case detection which requires further study. The impact of these findings likely extends to other diseases where diagnostics share similar vulnerabilities.

RESEARCH IN CONTEXT

Evidence before this study. We conducted two Pubmed searches for reports published after Jan 1, 2000, in all languages. The first search terms were [bacteriophage OR phage] AND [pathogen] AND [diagnostic test]. The primary search criteria identified 57 publications. A secondary criterion excluded reviews and papers on phage display technology. Among twenty remaining articles, bacteriophage were used as proxies for pathogens within diverse genera (Yersinia, Mycobacterium, Burkholderia, Staphylococcus, Salmonella, Bacillus, Escherichia, Acinetobacter, Vibrio); phage profiles were also used as biomarkers for infection. The second search terms were [rapid diagnostic test OR RDT] AND [Vibrio]. After excluding reviews, 101 papers were identified that covered immunologic (antibody-based lateral flow assays), molecular (PCR, qPCR, nl-qPCR) and mass spectrometry-based assays; only 5 articles related to vibriophage detection of which three were permutations of the same initiative.

Added value of this study. To our knowledge, this is the first study to investigate the vulnerabilities of RDT performance (e.g., sensitivity and specificity) to virulent bacteriophage and antibiotics in a large multi-site study. The hypothesis that antimicrobials and disease severity might impact RDT performance by decreasing or increasing the target number, respectively, is not novel. However, there is a lack of literature from large clinical studies that rigorously tests this hypothesis. Therefore, the added value of this study is a pragmatic evaluation of this hypothesis and a proof of concept for how to test these complex questions for other less tractable diseases.

Implications of all the available evidence. Inside the cholera field, we applied the findings by estimating that changing to a mode of restricted RDT use in which RDTs are reserved for severely dehydrated patients who report no antibiotic exposure,

49 significantly improves the sensitivity. Furthermore, we estimate that an additional 17%
50 of cases would be missed by RDT if the case definition were expanded to include phage
51 detection as a proxy for the pathogen. In this context, the RDT remains with limitations
52 that require consideration when optimizing global RDT deployments. Implications likely
53 extend to other diseases where diagnostics share similar vulnerabilities.
54

INTRODUCTION

Cholera causes an estimated 1.3 – 4 million symptomatic cases and 21,000 – 143,000 deaths annually[1]. Since the COVID-19 pandemic, cholera outbreaks expanded to over 44 countries[2] and the World Health Organization (WHO) declared a global emergency at its highest level (grade 3)[3]. In both endemic and non-endemic regions facing this crisis, access to 'gold-standard' culture and molecular based diagnostics at conventional laboratories is limited which can impede effective response. Accurate bedside rapid diagnostic tests (RDTs) offer a promising solution to this problem. In response, international agencies have subsequently operationalized large RDT deployments[4] for epidemiologic applications that include surveillance and optimization of vaccination campaigns[5,6].

Cholera is an acute watery diarrhoeal disease caused by the Gram-negative facultative anaerobe *Vibrio cholerae (Vc)*. Case fatality rates historically rose above 20% before intravenous fluids, but in the modern era can fall to less than 1% with use of oral rehydration solution (ORS) alone[7]. The current paradigm is that susceptible individuals become infected after exposure to contaminated food, fomites, or water. The exact infectious dose in humans is unknown and likely varies. In an infant mouse model, the infectious dose may be as low as 20 cells when the inoculum is human-shed *Vc*[8]. The infection may manifest in asymptomatic or symptomatic disease. The ratio of symptomatic to asymptomatic cases is thought to vary widely. In the endemic setting of Bangladesh, it is estimated there are 820 asymptomatic infections (or exposures) per symptomatic case[5].

77 Factors that influence cholera severity across the asymptomatic to symptomatic
78 spectrum includes the degree of prior exposure to *Vc*[7], antimicrobial exposures[9], and
79 effective predation by virulent bacteriophage (phage)[10]. The WHO Global Task Force on
80 Cholera Control (GTFCC) recommends antibiotic treatment (doxycycline (DOX),
81 azithromycin (AZI), or ciprofloxacin (CIP)) for more severe cases as a supportive
82 maneuver [11-14]. In practice, mass spectrometry revealed that nearly all cholera patients
83 in a setting like Bangladesh shed diverse antibiotics despite only half reporting
84 exposure[10,15,16]. Antibiotic resistance is common and spreads globally as cholera
85 spreads[17,18]. Virulent phages specific to *Vc* are relatively common and limited in number
86 (ICP1, 2, 3)[19-23]. *Vc* can harbor arrays of phage defense mechanisms, including BREX,
87 on a mobile integrative and conjugative element (ICE) which also harbors antibiotic
88 resistance factors. Phage in turn can harbor cognate antidefenses[24-27]. Phage can also
89 act synergistically or antagonistically with antibiotics to kill bacterial prey[28,29]. While a
90 phenotype called hyper-infectivity is thought to accelerate outbreaks, phage predation is
91 proposed to quench outbreaks although data are limited[30-35].
92 Culture and molecular (e.g., PCR, qPCR) assays are considered 'gold-standards' for
93 cholera diagnostics[36,37]. Adjunct commercialized RDTs typically are lateral flow devices
94 ('dipsticks') that rely on O-specific polysaccharide (OSP) specific antibodies (Abs)[37-39].
95 Guidelines restrict RDTs to epidemiologic and not clinical applications because of
96 variable performance with sensitivity ranging from 58-100% and specificity from 71-
97 100%[37,40-42]. Attempts to increase RDT performance by altering protocols and assembly
98 have had limited gains to extend their use to clinical decision making[40,41,43].
99 Explanations for the varied sensitivity include variations in disease severity,

100 antimicrobial exposure, and phage predation[36,37,9,44]. We previously found that the odds
101 of RDT positivity among cholera patients decreased by more than 80% when phage or
102 antibiotics were detected[9]. This vulnerability calls into question the value of RDTs in
103 their current form and method of use. Determining antimicrobial effects on performance
104 may offer opportunities to optimize deployment and extend use to clinical decision-
105 making.

106 Our objective herein was to evaluate two primary hypotheses: (i) Virulent phage and
107 antibiotic exposure negatively impact RDT performance. (ii) RDT performance positively
108 correlates with disease severity, defined using the WHO dehydration classifications of
109 mild, moderate and severe[45]. These two hypotheses are connected by target
110 concentration. The mechanisms might be a decrease in *Vc* targets below the RDT limit
111 of detection (LOD) for the first hypothesis versus an increase in *Vc* targets above the
112 LOD for the second hypothesis [10,46]. To test these hypotheses, we analyzed data from a
113 prospective clinical study conducted across Bangladesh whereby stool samples were
114 collected from patients admitted with diarrhoeal disease at district hospitals[47]. Clinical
115 metadata were paired with microbiologic and molecular data to detect and quantify *V.*
116 *cholerae* and associated phage; mass spectrometry was conducted on select samples
117 to objectively assess antibiotic effects. The results support our hypotheses exposing
118 critical RDT limitations while also revealing potential approaches that could optimize
119 global RDT deployments.

120 **MATERIALS AND METHODS**

121 **Ethics Statement**. Samples, and associated clinical data, were collected within two
122 previously published IRB approved clinical studies in Bangladesh: (i) The National

123 Cholera Surveillance (NCS) study (icddr,b ERC/RRC PR-15127)[48] and (ii) The mHealth
124 Diarrhea Management (mHDM) cluster randomized controlled trial (IEDCR
125 IRB/2017/10; icddr,b ERC/RRC PR-17036; University of Florida IRB 201601762) [47].

126 **Study Design.** The parent study for this secondary analysis was a prospective
127 longitudinal study of patients admitted with diarrhea at five Bangladesh Ministry of
128 Health and Family Welfare district hospitals (both NCS and mHDM sites) and two
129 centralized NCS hospitals (BITID; icddr,b) (**Fig S1)**. Sites were distributed nation-wide[49].
130 Samples were collected from March 2018 to December 2018. Samples were collected
131 until April 2019 at one site (icddr,b) where all assays were performed except RDTs.

132 **Laboratory procedures.** Stool samples were collected at admission. Aliquots were
133 stabbed into Cary-Blair transport media for subsequent culture at the icddr,b central
134 laboratory via standard methods[50]. Aliquots for molecular analysis were preserved in
135 75% RNAlater (Invitrogen); total nucleic acid (tNA) was extracted using standard
136 methods. Criteria and methodology for liquid chromatography-tandem mass
137 spectrometry (LC-MS/MS) to objectively assess antibiotics among all culture positive
138 and select culture negative samples were described previously[10]. In brief, criteria were
139 (i) culture positive for *Vc*, (ii) phage (ICP1,2,3) positive by PCR among culture-negative
140 samples, or (iii) *Vc* positive by PCR (*ompW* target) among a random 10% of those
141 samples negative by culture for *Vc* and by PCR for phage (**Fig S2**). Common antibiotics
142 targeted for LC-MS/MS were based on prior research[10,15]. Ciprofloxacin,
143 doxycycline/tetracycline, and azithromycin, metronidazole and nalidixic acid were
144 analyzed qualitatively. For quantitative analysis of ciprofloxacin,
145 doxycycline/tetracycline, and azithromycin, standard curves were prepared by dilution

146 series of the native and isotopic forms of targets. Each stool sample was spiked with the
147 isotopic mixture as an internal reference control. Quantitative results were binned by
148 effective concentration and ineffective concentration; the definition of effective
149 concentration was based on the lowest minimal inhibitory concentration (MIC) in a prior
150 strain collection[51]. To provide additional insight after the PCR analysis, quantitative PCR
151 (qPCR) was subsequently performed on all available samples to enumerate absolute
152 abundances of *Vc* (*tcpA*), ICP1 (GP58.2), ICP2 (GP24), and ICP3 (GP19) using
153 methods previously described[10]. Estimates for CFU/ml were derived using the qPCR Ct
154 values from standard curves of serial dilutions of cultured *V. cholerae.* Stool samples
155 were tested with the Cholkit (Incepta Pharmaceuticals, Bangladesh), an RDT that
156 targets the detection of *V. cholerae* O1 OPS using a standardized method[39,52]. In brief,
157 five drops of watery stool were added to the diluent supplied in a microcentrifuge tube.
158 The RDT strip was then dipped into the stool-diluent mixture for 15 minutes. *V. cholerae*
159 O1 detection was confirmed 'by eye' for the appearance of both test and control lines[39].
160 Solid stools were not tested; cholera RDTs in general, including the Cholkit, are not
161 designed to test solid stools.
162 **Statistical analyses.** Statistics and visualizations were done in GraphPad Prism
163 version 10.2.3 and R version 4.4.2[53]. The "Eulerr" package was used to create **Figure**
164 **1A** for samples with all relevant test results available[54]. Test performance metrics
165 (sensitivity, specificity, positive predictive value, negative predictive value) and
166 corresponding exact binomial confidence limits were calculated in the "epiR" package[55].
167 Standardized predictive values were calculated by using the observed diagnostic
168 sensitivity and specificity in the given subgroup and calculating the predictive value that

169 would have been observed if disease prevalence was 50% in that subgroup. We used
170 unadjusted generalized linear models with a binomial error distribution and logit link to
171 estimate odds ratios and corresponding 95% confidence intervals. Fisher's exact test
172 was used to calculate p-values where indicated.

173 **RESULTS**

174 **Study overview.** A total of 2574 participants were enrolled at seven hospitals across
175 Bangladesh from March to December 2018, with one stool sample collected from each
176 participant (**Figs S1 and S2**). Enrollment continued at one site (icddr,b) until April 2019.
177 Although RDTs were not performed at the icddr,b, samples were included to better
178 assess phage and *Vc* relationships by qPCR. RDTs were performed on each of the
179 remaining 2180 samples of which all had culture and 2078 had *Vc* qPCR **(Table 1)**.
180 Specific to testing our two hypotheses: (i) ICP1, ICP2, and ICP3 were detected among
181 137, 10, and 86 participants, respectively, and (ii) the number of participants with mild,
182 moderate and severe dehydration was 392, 1193 and 493, respectively. LC-MS/MS for
183 antibiotic detection was attempted and successful on all culture positive samples and a
184 subset of culture negative samples (446) [10,15,51] **(Fig S2).**

185 **Characterization and comparison of assays for *Vc* detection.** Among samples with
186 all assays performed, there was discordance in *Vc* detection by assay type (**Fig 1A**).
187 Out of 2078 samples with both *Vc* culture and qPCR, only 5.8% (120) of samples were
188 positive for *Vc* by both culture and qPCR. An additional 13.2% (274) of samples were
189 negative by culture and positive by qPCR, and 2.6% (55) of samples were positive by
190 culture and negative by qPCR. The concentration of *Vc* at which 50% of the RDTs
191 tested positive (diagnostic dose 50 or 'DD_{50}') was 1.93 x 10^8 CFU/ml; The percentage

192 of positive RDTs increased with *Vc* concentration binned by order of magnitude (**Fig**
193 **1B**).
194 **Distribution of phage among samples with and without *Vc*.** Among samples with all
195 assays performed, ICP1, ICP2 and ICP3 were detected by qPCR in 137, 10 and 76
196 samples, respectively (**Table 1**). These analyses include samples that were positive or
197 negative for *Vc*. In the absence of *Vc* (culture or qPCR), ICP1, ICP2, and ICP3 were
198 detected in 2.1% (43), 0.2% (4), and 3.1% (64) of samples respectively (**Fig 1A**); unless
199 specified, analyses focused on ICP1 and ICP3 because of the larger sample sizes. We
200 next analyzed quantitative associations between phage and *Vc.* Data are visualized in
201 quadrants by *Vc* and/or phage detection using a Ct threshold of 28 (**Fig 1C, D**).
202 Samples that did not have RDT results (gray 'x') were included to better elicit patterns in
203 the data. For both ICP1 and ICP3, increasing *Vc* detection was associated with
204 increasing phage detection. Among those samples with RDT results, the percentages of
205 RDT positive samples are shown in each quadrant. The quadrants with the least
206 percentage of RDT positive samples were those with phage detection alone.
207 **Effect of phage predation on RDT performance.** Among cholera samples defined
208 conventionally by *Vc* qPCR or culture, RDT sensitivity (46%) and specificity (85%) did
209 not differ when phage positive samples were excluded (**Table 2**). PPV and NPV were
210 respectively higher and lower among samples with ICP1 compared to other groups
211 (e.g., samples without phage). However, this effect was driven by differences in cholera
212 prevalence between groups, and resolved once predictive values were assessed at a
213 standardized prevalence. Among samples with ICP3, sensitivity decreased compared to
214 samples without phage yet confidence intervals overlapped. While culture and qPCR

are the current reference standards, the detection of cholera-specific phage among samples negative for *Vc* suggested the conventional definition may inappropriately exclude cases. Therefore, we explored an expanded definition that included phage detection as a proxy for *Vc* for situations when the primary *Vc* target might be highly degraded. The inclusion of phage in the diagnostic criteria resulted in a modest effect on the RDT (**Table S1**); the sensitivity decreased from 0.46 (95%CI 0.41–0.51) to 0.38 (95%CI 0.34-0.42). Despite this seemingly small effect on sensitivity, we estimated RDTs would miss an additional 17% of 'true' cholera cases if the diagnostic reference standard were expanded to include "phage only" as cholera cases.

Effect of dehydration severity on RDT performance. We evaluated the impact of dehydration severity on RDT performance. The median concentrations of *Vc* (CFU/ml) derived from those samples positive by qPCR at mild, moderate or severe levels of dehydration were 3.25×10^7 (IQR 8.60×10^6 to 1.14×10^9), 1.05×10^8 (IQR 1.06×10^7 to 2.16×10^9) and 1.00×10^8 (IQR 8.34×10^6 to 4.41×10^9), respectively. In this context, RDT performance increased sequentially from patients with mild to moderate to severe dehydration (**Table 3**). RDT sensitivity was 0.25 (95% CI: 0.16, 0.37) in those mildly dehydrated, compared to 0.63 (95% CI: 0.54, 0.71) in samples from severely dehydrated patients. Specificity also increased between mild cases and cases with moderate or severe dehydration. Standardized predictive values, both positive and negative, also increased significantly in severely dehydrated patients compared to mildly dehydrated patients.

Effect of phage on the RDT performance at different dehydration levels. We explored if the effect of phage on RDT performance varied by dehydration status

238 (possible effect modification) **(Table 4)**. Among *Vc* positive patients (culture or qPCR),
239 phage exposure was not associated with RDT positivity as an aggregate or by severity
240 level. When the case definition was expanded to include phage detection, the odds of
241 RDT positivity were significantly lower in those with phage compared to those without
242 phage (OR 0.377; 95%CI 0.217-0.642). This effect was observed among samples from
243 moderately and severely dehydrated cases, but not from mildly dehydrated cases. The
244 effect also differed by phage type used in the case definition. The effect of phage on
245 RDT positivity was most prominent among those samples positive by culture, qPCR, or
246 ICP3 (OR 0.099; 95%CI 0.023-0.292). The impact of dehydration status on this
247 relationship between phage presence and RDT performance (effect modification) was
248 also strongest with this expanded definition.
249 **Effect of antibiotic exposure on RDT performance.** Large discordance between self-
250 reported and LC-MS/MS-detected antibiotic exposures was observed. Among those
251 with complete diagnostics, 46% of patients (956/2078) self-reported antibiotic exposure
252 and 87% (220/252) of select samples assayed by LC-MS/MS (**Fig S2**) contained
253 antibiotics. Among the WHO recommended antibiotics, ciprofloxacin was the most
254 commonly self-reported antibiotic (27%; 568) followed by azithromycin (14%; 289) with
255 no participant self-reporting doxycycline use (**Table S2**). RDT performance was
256 consistent across all types of self-reported antibiotic exposure, including no self-
257 reported antibiotic exposure. To take a more objective approach, LC-MS/MS was used
258 to detect exposure to common antibiotics (CIP, AZI, DOX, metronidazole (MET), or
259 nalidixic acid (NAL) which were detected in 81% (178/220) of samples tested (**Table
260 S2**). The small proportion of samples that did not have antibiotics detected by LC-

261 MS/MS limited analyses on the effects of antibiotics on RDT performance. Despite this
262 challenge, RDT sensitivity among samples with AZI at or above the 'effective
263 concentration' was 0.33 (95%CI 0.13-0.59) compared to 0.67 (95%CI 0.47-0.83) among
264 samples without antibiotic (**Table S2**). Among *Vc* positive samples, antibiotic resistance
265 had no effect on the odds of RDT positivity with or without AZI exposure, however
266 samples sizes were small (**Table S3**).

267 **Estimates of RDT performance in different modes of deployment.** We sought to
268 estimate and compare RDT performance in different modes of deployment (**Table 5**).
269 We considered an unrestricted mode in which all patients are tested. We compared this
270 to a more restricted mode that would rely on data accessible at the bedside through the
271 clinical history (self-reported antibiotic exposure) or the physical exam (dehydration
272 status). Despite phage detection not being accessible at the bedside, it is reasonable to
273 consider it as a potential component to include in molecular diagnostic panels in the
274 future. LC-MS/MS is too expensive and complex for consideration. In this context, we
275 found that RDT sensitivity increases from 0.46 (95%CI: 0.41-0.51) among all patients to
276 0.69 (95%CI: 0.57-0.80) when use is restricted to patients that report no antibiotic
277 exposure and have severe dehydration. When the case definition is expanded to
278 include phage, RDT sensitivity also increases between restricted and unrestricted
279 modes. Modest effects were observed on PPV and NPV depending on case definition
280 and mode of use.

281 **DISCUSSION**

282 Effective cholera control is aided by accurate bedside rapid diagnostic tests (RDTs).
283 Here we conducted a secondary analysis of a prospective cohort study of patients with

284 diarrhoeal disease to test if virulent bacteriophage (phage) impact RDT performance
285 and determine if there are tractable approaches to optimize RDT use. With the current
286 gold standard of culture or qPCR *Vc* positivity, we found no significant effect of phage
287 on RDT performance. When the reference standard was expanded to include phage,
288 there was a small decrease in RDT sensitivity. In contrast, significantly higher sensitivity
289 and specificity were found among patients with moderate or severe dehydration. Using
290 the expanded definition of including phage detection, the odds of RDT positivity among
291 cholera patients decreased by 57% with phage exposure and the effect was most
292 robust among patients with severe dehydration. These findings align with our guiding
293 hypotheses as well as pose intriguing questions on how one might apply these results
294 to optimize RDT deployments.

295 Our first hypothesis was that virulent phage and antibiotic exposure negatively
296 impact RDT diagnostic performance. RDT sensitivity and specificity were not
297 appreciatively impacted when samples with phage were removed from the analysis.
298 Among ICP1 positive samples, PPV and NPV increased and decreased respectively
299 using the current gold standard case definition. This likely reflects an increased pretest
300 probability for *Vc*; standardizing rates of *Vc* removed the effect. Among ICP3 positive
301 samples, sensitivity and PPV were decreased however confidence intervals overlapped;
302 standardizing rates of *Vc* removed the effect on PPV. We next expanded the case
303 definition to include phage detection. Inclusion of phage in the diagnostic criteria had
304 modest effects that aligned with our guiding hypotheses.

305 Our second hypothesis was that RDT performance positively correlates with
306 disease severity. The rationale is based on our prior study of the predator (phage) --

307 prey (*Vc*) dynamics along the disease severity spectrum; the prior study found high
308 abundance of *Vc* was correlated with severe disease[10]. In contrast to the modest effects
309 of phage, significant increases in sensitivity and specificity were found among patients
310 with moderate or severe dehydration. This finding likely reflects that samples from more
311 severe patients had higher concentrations of *Vc* at levels that we showed above have a
312 higher percentage of RDT positivity.

313 The lack of congruence between the assays performed (culture, qPCR, RDTs)
314 may reflect complex underlying biologic events and not simply variation in assay
315 assembly and manipulation. Mechanistically, we propose that false positive RDTs may
316 be more common among mild cases because the concentration of *Vc* is low and non-*Vc*
317 microbiota is high which may increase cross-reactivity of the immunologic epitopes.
318 Although cross-reactivity may occur using molecular assays, cross-reactivity for the
319 qPCR primer set used was likely low based on our prior study[10]; that said degradation of
320 the nucleic acid impacts molecular assays which we attempted to mitigate by stabilizing
321 the samples. Culture is a definitive assay for *Vc* but sensitivity can decrease because of
322 processing delays, antibiotic exposure and possibly phage predation. In this context, we
323 evaluated the interactions between phage predation and disease severity. Using the
324 expanded case definition that includes phage detection, we found that the odds of RDT
325 positivity among cholera patients decreased by 63% with phage exposure. The effect
326 was most robust among patients with severe dehydration and varied by phage type;
327 ICP3 dramatically decreased the odds of RDT positivity among cholera patients. One
328 explanation for this effect of among severely dehydration patients with ICP3 is that there
329 is simply more prey for the predator among severely dehydration patients and the effect

330 is more easily detected. Among patients with mild disease, there may simply be
331 insufficient *Vc* for the RDT to detect independent of phage predation.
332 Both clinicians and epidemiologists face two key questions based on these
333 findings. The first question is whether to include phage detection in cholera diagnostic
334 panels as a proxy for detection of the pathogen when phage degrade the pathogen
335 below the limit of detection for a given assay. The benefits (e.g. overall increased case
336 detection) versus risks (e.g. increased cost) need consideration by both clinicians and
337 epidemiologists. The second question is how to best validate and incorporate these
338 findings as RDTs are being deployed globally to combat cholera. For validation, studies
339 in diverse clinical and epidemiologic scenarios are needed. For deployment, we
340 estimated the effects of restricting RDT use to patients who report no antibiotic use and
341 have severe dehydration. In this context, sensitivity had a relative increase of
342 approximately 50%, independent of consideration of phage predation. This restriction
343 may represent a strategy to conserve RDTs in resource limited situations. However, this
344 restriction may also miss non-severe disease that play an important role in transmission
345 or mortality in the convalescent period.
346 These findings should be considered within the limitations of the study. First, LC-
347 MS/MS was not performed on all samples because of logistical limitations. Among *Vc* or
348 phage positive samples, LMCS found antibiotics were common and the distributions of
349 samples were insufficient to disaggregate the effects of phage and antibiotics on RDT
350 performance; proposing to restrict RDT use to those without antibiotic exposure is in
351 some aspects empiric. Second, the recruitment and enrollment of patients within the
352 parent clinical trial was based on the census of patients that sought care. This may a

353 potential recruitment bias. Those patients that sought care are not considered
354 representative of all infected individuals in the community. Third, clinical exams were
355 conducted in district hospitals using WHO and Bangladesh Ministry of Health and
356 Family Welfare guidelines. These guidelines have varied accuracy; this study would
357 likely be improved by incorporating more accurate measures of dehydration[56]. Fourth,
358 the approach had experimental limitations: The analyses excluded host factors such as
359 innate and acquired immunity. Control assays were not performed on
360 asymptomatic/healthy participants in the community. Solid stools were not assayed.
361 Despite these limitations, the findings provide important actionable insights. Future time-
362 series studies of patients over the disease course and recovery period in endemic and
363 non-endemic settings would assist testing our guiding hypotheses and address study
364 limitations.

365 **CONCLUSION**

366 Herein, we found RDT performance was minimally impacted by phage overall and
367 significantly increased among severely dehydrated patients. Expanding the case
368 definition to include phage, the odds of RDT test positivity decreased significantly. We
369 favor the expanded case definition that includes phage while recognizing the need for
370 future investigation. Lastly, we provide estimates on the applied effects of restricted vs
371 non-restricted RDT deployment. The significance of these findings may extend broadly
372 to other disease where diagnostics share similar vulnerabilities.

Data availability. Available upon request.

Code availability. Available upon request.

Acknowledgements: We thank the patients for their participation. We thank the diligent clinical and laboratory team members who were essential to the success of the study. We are grateful to the Institute of Epidemiology, Disease Control and Research (IEDCR), Ministry of Health and Family Welfare, and Government of Bangladesh who collaborated on the original parent clinical studies. We are also grateful to the Governments of Bangladesh and Canada for providing unrestricted support to the icddr,b. We are grateful to B. Johnson, T. Linn, N. Rushing and K. Berquist for their administrative guidance at the University of Florida.

Funding: The laboratory procedures were funded by a Wellcome Trust grant to EJN [DFID grant 215676/Z] and National Institutes of Health grants to KBB [S10 OD021758-01A1] and DS [R01 AI123422-06A1]. Statistical analysis was funded in part by a grant from the Thrasher Research Fund to SMA. The parent clinical study was supported by National Institutes of Health grants to EJN [R21TW010182]. The funders had no role in the study design, data collection, statistical analyses, decision to publish, or preparation of the manuscript.

Author contributions:

Conceptualization: SMA, MAS, FQ, JA, AIK, EJN

Implementation of clinical study: MAS, FQ, AIK, EJN

Lab procedures: MAS, ETC, ACM, KI, MIUK, MTRB, YB, EF, AV, LB, MK, LSB, EJN

Statistical analyses and visualizations: SMA, NM, BJS, JA, EJN

Funding acquisition: SMA, DS, KBS, EJN

Supervision: KBS, BJS, FQ, AIK, EJN

Writing – original draft: SMA, EJN

Writing – review & editing: SMA, MAS, DS, AKD, JA, FQ, AIK, EJN

Competing interests: Authors declare that they have no competing interests.

400 **FIGURES**

401 **FIGURE 1**



402

403 **Fig. 1. Comparison of target detection by different diagnostics. A** Euler plot displaying
404 overlaps between positive diagnostics. Given limitations with Euler plots, the following positive
405 values are not shown in the figure: only Vc culture (n= 35/175 total culture positives; 25%), only
406 ICP2 qPCR (n=4/10 total ICP2 positives; 40%), only Vc culture and Vc qPCR tcpA (n=18), only
407 RDT and ICP1 qPCR (n=4), and only Vc qPCR tcpA and ICP3 qPCR (n=9). **B**. Linear
408 regression analysis of relationship between $\log_{10}$ *Vc* abundance (CFU/ml) derived from *tcpA*
409 qPCR and RDT positivity. Samples were binned into five groups based on *Vc* concentration:
410 less than $1x10^7$, 1-9 x 10^7, 1-9 x 10^8, 1-9 x 10^9, and above $1x10^{10}$ CFU/ml. In a given group,
411 each symbol is plotted by the median concentration (X coordinate) by the proportion of samples
412 RDT positive (Y coordinate). The *Vc* dose at which 50% of RDTs ('DD_{50}') were positive (gray
413 dotted line at 1.93 $x10^8$ CFU/ml). Line of best fit is shown and fit using least squares regression
414 (95% CIs shown). **C.** Comparison of qPCR Ct values for *Vc* (*tcpA*) with ICP1. **D.** Comparison of
415 qPCR Ct values for *Vc* (*tcpA*) with ICP3 (GP19). For C and D: Quadrants are demarcated by
416 phage (Ph) and *Vc* positivity (+) with the percentage RDT positive per quadrant. Gray dotted
417 lines = thresholds for positive (Ct = 28). "X" = no RDT performed; hollow colored circle = RDT+,
418 hollow gray circle = RDT-. Tick shows dose at which 50% of all RDTs are positive (DD_{50}).

419 **Table 1. Overview of participants characteristics by RDT result**

Characteristic	RDT Negative *n*= 1632[a] (total)	RDT Positive *n*= 446[a] (total)
Site		
Habiganj[b] (#2)	328 (20.1%)	177 (39.7%)
Naogaon[b] (#4)	227 (13.9%)	48 (10.8%)
Patuakhali[b] (#5)	188 (11.5%)	40 (9.0%)
Comilla[b] (#15)	169 (10.4%)	18 (4.0%)
Kusthia[b] (#17)	458 (28.1%)	99 (22.2%)
Chittagong (BITID; #10)	262 (16.1%)	64 (14.3%)
Sex, n (%)		
Male (#1)	810 (49.6%)	226 (50.7%)
Female (#2)	822 (50.4%)	220 (49.3%)
Age (months), median (IQR)	300 (15.0-480)	240 (14.0-420)
Age, n (%)		
0-11 months	270 (16.5%)	78 (17.5%)
1-4 years	319 (19.5%)	82 (18.4%)
5-64 years	968 (59.3%)	277 (62.1%)
65+ years	75 (4.6%)	9 (2.0%)
Dehydration status		
Mild	302 (18.5%)	90 (20.2%)
Some	965 (59.1%)	228 (51.1%)
Severe	365 (22.4%)	128 (28.7%)
Culture, *n* (%)		
Negative	1574 (96.4%)	329 (73.8%)
Positive	58 (3.6%)	117 (26.2%)
qPCR, *n* (%)		
Vc (*tcpA*) negative	1426 (87.4%)	258 (57.8%)
Vc (*tcpA*) positive	206 (12.6%)	188 (42.2%)
ICP1 (GP58.2) negative	1544 (94.6%)	397 (89.0%)
ICP1 (GP58.2) positive	88 (5.4%)	49 (11.0%)
ICP2 (GP24) negative	1627 (99.7%)	441 (98.9%)
ICP2 (GP24) positive	5 (0.3%)	5 (1.1%)
ICP3 (GP19) negative	1557 (95.4%)	435 (97.5%)
ICP3 (GP19) positive	75 (4.6%)	11 (2.5%)
Self-reported antibiotic use		
No	877 (53.7%)	245 (54.9%)
Yes	755 (46.3%)	201 (45.1%)

420 [a] Values for those samples in which cultures, qPCR (*tcpA*, ICP1, ICP2, ICP3)
421 and RDT were performed out of the given total. Excludes samples from Dhaka
422 samples (n=394) because RDTs were not performed at this site
423 [b] Ministry of Health and Family Welfare, Government of Bangladesh District
424 Hospitals. Icddr,b = International Centre for Diarrhoeal Disease Research,
425 Bangladesh. BITID = Bangladesh Institute of Tropical Infectious Diseases.

426 **Table 2. Effect of phage predation on RDT performance**

Sample type	All	No phage [a]	ICP1 phage positive	ICP3 phage positive
Vc+/total (%)[b]	449 / 2078 (21.6)	345 / 1852 (18.6)	89 / 137 (65.0)	15 / 86 (17.4)
Sensitivity	0.46 (0.41, 0.51)	0.46 (0.40, 0.51)	0.49 (0.39, 0.60)	0.27 (0.08, 0.55)
Specificity	0.85 (0.84, 0.87)	0.85 (0.83, 0.87)	0.90 (0.77, 0.97)	0.90 (0.81, 0.96)
PPV_{obs}[c]	0.46 (0.42, 0.51)	0.41 (0.36, 0.46)	**0.90 (0.78, 0.97)**	0.36 (0.11, 0.69)
NPV_{obs}[c]	0.85 (0.83, 0.87)	0.87 (0.85, 0.89)	**0.49 (0.38, 0.60)**	0.85 (0.75, 0.92)
PPV_{50}[c]	0.76 (0.72, 0.79)	0.75 (0.71, 0.79)	0.83 (0.68, 0.93)	0.73 (0.45, 0.92)
NPV_{50}[c]	0.61 (0.59, 0.64)	0.61 (0.58, 0.64)	0.64 (0.53, 0.73)	0.55 (0.43, 0.67)

427 [a] ICP1, ICP2, and ICP3 not detected
428 [b] Number positive for *Vc by* culture or qPCR (*tcpA*) as the gold reference standard over total number
429 samples in grouping
430 [c] Subscript indicates the proportion of samples that were gold-standard positive
431 in the given group for the calculation of each predictive value, with
432 "obs"=observed and "50"=50%. For example, PPV_{50} or standardized positive
433 predictive value indicates the positive predictive value of RDT in each group if
434 50% of that group was gold-standard positive for cholera.
435
436
437
438 **Table 3. Effect of dehydration severity on RDT performance**

	Mild (comparator)[a]	Moderate[a]	Severe[a]
Vc+/total (%)[b]	75 / 392 (19.1)[c]	236 / 1193 (19.8)[c]	138 / 493 (28.0)[c]
Sensitivity	0.25 (0.16, 0.37)	0.43 (0.36, 0.49)	**0.63 (0.54, 0.71)**
Specificity	0.78 (0.73, 0.82)	**0.87 (0.84, 0.89)**	**0.88 (0.85, 0.92)**
PPV_{obs}[d]	0.21 (0.13, 0.31)	**0.44 (0.38, 0.51)**	**0.68 (0.59, 0.76)**
NPV_{obs}[d]	0.81 (0.77, 0.86)	0.86 (0.84, 0.88)	0.86 (0.82, 0.89)
PPV_{50}[d]	0.53 (0.42, 0.63)	**0.76 (0.71, 0.81)**	**0.85 (0.78, 0.89)**
NPV_{50}[d]	0.51 (0.45, 0.57)	**0.60 (0.57, 0.64)**	**0.71 (0.65, 0.76)**

439 [a] Mild, moderate and severe dehydration approximate 0-4%, 5-9% and 10%+ loss to normal body due to
440 diarrhoeal fluid loss per WHO guidelines.
441 [b] Number positive for *Vc by* culture or qPCR (*tcpA*) as the gold reference standard over total number
442 samples in grouping
443 [c] The concentration of *Vc* derived from qPCR data among patients with mild, moderate and severe
444 dehydration is 3.25×10^7 (IQR 8.60×10^6 to 1.14×10^9), 1.05×10^8 (1.06×10^7 to 2.16×10^9) and $1.00 \times$
445 10^8 (8.34×10^6 to 4.41×10^9), respectively.
446 [d] Defined in Table 2.
447

448 **Table 4. Effect of phage exposure on RDT positivity among cholera patients**

Case definition	n	% RDT positive (n/ total) Phage Exposed	Unexposed	OR[a]	CI[a]	*P* value[a]
Vc positive[a]						
All	197	46 (22/48)	46 (69/149)	0.981	0.508-1.88	0.954
Mild	43	6 (1/16)	15 (4/27)	0.383	0.019-2.91	0.411
Moderate	86	57 (8/14)	42 (30/72)	1.867	0.589-6.21	0.291
Severe	68	72 (13/18)	70 (35/50)	1.114	0.349-3.97	0.859
Vc positive or phage positive (ICP1,2,3)[a]						
All	259	25 (27/110)	46 (69/149)	**0.377**	**0.217-0.642**	**<0.001**
Mild	62	14 (5/35)	15 (4/27)	0.958	0.229-4.25	0.953
Moderate	113	20 (8/41)	42 (30/72)	**0.339**	**0.130-0.809**	**0.019**
Severe	84	41 (14/34)	70 (35/50)	**0.300**	**0.118-0.737**	**0.010**
Vc positive or ICP1 positive[a]						
All	218	32 (22/69)	46 (69/149)	**0.543**	**0.294-0.980**	**0.046**
Mild	57	13 (4/30)	15 (4/27)	0.885	0.189-4.13	0.872
Moderate	93	33 (7/21)	42 (30/72)	0.700	0.240-1.90	0.494
Severe	68	61 (11/18)	70 (35/50)	0.673	0.220-2.14	0.491
Vc positive or ICP3 positive[a]						
All	187	8 (3/38)	46 (69/149)	**0.099**	**0.023-0.292**	**<0.001**
Mild	32	20 (1/5)	15 (4/27)	1.44	0.065-13.6	0.770
Moderate	91	5 (1/19)	42 (30/72)	**0.078**	**0.004-0.409**	**0.015**
Severe	64	7 (1/14)	70 (35/50)	**0.033**	**0.002-0.188**	**0.002**

449 [a]Reference standard to define positive cholera cases for analysis within a given group. "*Vc* positive" is defined as
450 positive by culture or qPCR. *P* values were computed using logistic regression (see methods).
451
452
453

454
455 **Table 5. Estimates of RDT performance in different modes of deployment**

Approach	Unrestricted (comparator)	Use clinical exam	Use patient history and exam	Use clinical exam	Use patient history and exam
Restriction	None	Moderate and severe cases	Moderate and severe cases AND no reported antibiotic use	Severe cases	Severe cases AND no reported antibiotics use
Case definition (current gold standard): culture or qPCR for *Vc*					
Cases/total (%)	449 / 2078 (21.6)	374 / 1686 (22.2)	168 / 863 (19.5)	138 / 493 (28.0)	72 / 266 (27.1)
Sensitivity	0.46 (0.41, 0.51)	0.50 (0.45, 0.55)	0.54 (0.46, 0.61)	**0.63 (0.54, 0.71)**	**0.69 (0.57, 0.80)**
Specificity	0.85 (0.84, 0.87)	0.87 (0.85, 0.89)	0.86 (0.83, 0.89)	0.88 (0.85, 0.92)	0.86 (0.80, 0.91)
PPV_{obs}[b]	0.46 (0.42, 0.51)	0.53 (0.47, 0.58)	0.48 (0.41, 0.56)	**0.68 (0.59, 0.76)**	**0.65 (0.53, 0.75)**
NPV_{obs}[b]	0.85 (0.83, 0.87)	0.86 (0.84, 0.88)	0.88 (0.86, 0.91)	0.86 (0.82, 0.89)	0.88 (0.83, 0.93)
PPV_{50}[b]	0.76 (0.72, 0.79)	0.80 (0.76, 0.83)	0.79 (0.74, 0.84)	0.85 (0.78, 0.89)	0.83 (0.75, 0.90)
NPV_{50}[b]	0.61 (0.59, 0.64)	0.64 (0.61, 0.66)	0.65 (0.61, 0.69)	**0.71 (0.65, 0.76)**	**0.74 (0.66, 0.81)**
Case definition (expanded standard): culture or qPCR for *Vc* OR qPCR for ICP1/ICP3 phage					
Cases/ total (%)	567 / 2078 (27.3)	469 / 1686 (27.8)	216 / 863 (25.0)	173 / 493 (35.1)	89 / 266 (33.5)
Sensitivity	0.38 (0.34, 0.43)	0.41 (0.37, 0.46)	0.43 (0.36, 0.50)	**0.51 (0.43, 0.59)**	**0.57 (0.46, 0.68)**
Specificity	0.85 (0.83, 0.87)	0.87 (0.85, 0.89)	0.85 (0.82, 0.88)	0.88 (0.83, 0.91)	0.85 (0.79, 0.90)
PPV_{obs}[b]	0.49 (0.44, 0.54)	0.54 (0.49, 0.60)	0.49 (0.42, 0.57)	**0.69 (0.60, 0.77)**	**0.66 (0.55, 0.77)**
NPV_{obs}[d\b]	0.79 (0.77, 0.81)	0.79 (0.77, 0.81)	0.82 (0.79, 0.85)	0.77 (0.72, 0.81)	0.80 (0.73, 0.85)
PPV_{50}[b]	0.72 (0.68, 0.76)	0.76 (0.71, 0.80)	0.74 (0.68, 0.80)	0.80 (0.73, 0.86)	0.80 (0.70, 0.87)
NPV_{50}[b]	0.58 (0.55, 0.60)	0.60 (0.57, 0.62)	0.60 (0.56, 0.64)	0.64 (0.59, 0.69)	0.67 (0.59, 0.74)

456 [a] Shaded text represents the current unrestricted standard of RDT use using qPCR and culture for *Vc* as
457 the reference standard. Bold text compares performance horizontally between unrestricted and restricted
458 approaches; underlined text vertically compares sensitivity when the reference standard is expanded to
459 include the detection of phages by qPCR (ICP1/3)
460 [b] Defined in Table 2.
461
462

SUPPLEMENTARY MATERIALS

Supplementary Figures

Figure S1. Study Map



Fig S1. Study site locations across Bangladesh. Red circles = RDT performed; gray circle = RDT not performed. Numbers in brackets correlate with site numbers in Table 1.

474 **Figure S2. Sample processing diagram**

475
476
477



478
479
480

481 **Figure S2. Sample processing diagram.** Schematic of the number of samples collected from patients admitted with
482 diarrhoeal disease (one per patient). * Those samples with RDTs (2180) are represented in the flow diagram; RDTs were
483 not performed at the icddr,b. ** Seven samples were excluded from further analysis (AMR testing and LC-MS/MS)
484 because they were misclassified as culture negative.

485 **Supplementary Tables**

486

487 **Table S1. Comparison of RDT performance using different diagnostic criteria for cholera**

	Vc (culture or qPCR)	*Vc* or ICP1 (qPCR)	*Vc* or ICP3 (qPCR)	*Vc* or ICP1 or ICP3[a]
Cases/total (%)[b]	449 / 2078 (21.6)	497 / 2078 (23.9)	520 / 2078 (25.0)	567 / 2078 (27.3)
Sensitivity	0.46 (0.41, 0.51)	0.43 (0.38, 0.47)	0.41 (0.37, 0.45)	0.38 (0.34, 0.43)
Specificity	0.85 (0.84, 0.87)	0.85 (0.83, 0.87)	0.85 (0.83, 0.87)	0.85 (0.83, 0.87)
PPV_{obs}[c]	0.47 (0.42, 0.51)	0.48 (0.43, 0.52)	0.48 (0.43, 0.53)	0.49 (0.44, 0.54)
NPV_{obs}[c]	0.85 (0.83, 0.87)	0.83 (0.81, 0.84)	0.81 (0.79, 0.83)	0.79 (0.77, 0.81)
PPV_{50}[c]	0.76 (0.72, 0.79)	0.74 (0.71, 0.78)	0.73 (0.70, 0.77)	0.72 (0.68, 0.76)
NPV_{50}[c]	0.61 (0.59, 0.64)	0.60 (0.57, 0.62)	0.59 (0.57, 0.62)	0.58 (0.55, 0.60)

488 [a] Independent of ICP2 detection

489 [b] Number positive for *Vc by* culture or qPCR (*tcpA*) as the gold reference standard over total number samples in grouping

490 [c] Subscript indicates the proportion of samples that were gold-standard positive in the given group for the calculation of
491 each predictive value, with “obs”=observed and “50”=50%. For example, PPV_{50} or standardized positive predictive value
492 indicates the positive predictive value of RDT in each group if 50% of that group was gold-standard positive for cholera.

493

494

495 **Table S2. RDT performance as a function of antibiotic exposure**

Exposure:	Reference	Antibiotic (any)	Ciprofloxacin		Azithromycin		Doxycycline/Tetracycline[a]	
	No antibiotic	Exposure	Reported vs Detected	At effective Concentration[b]	Reported vs Detected	At effective Concentration[b]	Reported vs Detected	At effective Concent.[b]
Self-reported (all patients)								
Vc+/total(%)[c]	210 / 1122 (18.7)	239 / 956 (25.0)	159 / 568 (28.0)	---	58 / 289 (20.1)	---	---	---
Sensitivity	0.46 (0.39, 0.53)	0.46 (0.40, 0.53)	0.48 (0.40, 0.56)	---	0.43 (0.30, 0.57)	---	---	---
Specificity	0.84 (0.81, 0.86)	0.87 (0.85, 0.90)	0.89 (0.86, 0.92)	---	0.87 (0.82, 0.91)	---	---	---
PPV_{obs}[d]	0.39 (0.33, 0.46)	0.55 (0.48, 0.62)	0.63 (0.54, 0.71)	---	0.45 (0.32, 0.59)	---	---	---
NPV_{obs}[d]	0.87 (0.85, 0.89)	0.83 (0.80, 0.86)	0.81 (0.78, 0.85)	---	0.86 (0.81, 0.90)	---	---	---
PPV_{50}[d]	0.74 (0.69, 0.78)	0.79 (0.73, 0.83)	0.81 (0.75, 0.87)		0.77 (0.66, 0.85)			
NPV_{50}[d]	0.61 (0.57, 0.64)	0.62 (0.58, 0.66)	0.63 (0.58, 0.68)		0.60 (0.53, 0.67)			
Detected by Mass Spectrometry (cholera patients only[e])								
Vc+/total(%)[a]	30 / 32 (93.8)	178 / 220 (80.9)	118 / 148 (79.7)	86 / 116 (74.1)	47 / 68 (69.1)	18 / 32 (56.3)	41 / 45 (91.1)	6 / 7 (85.7)
Sensitivity	0.67 (0.47, 0.83)	0.60 (0.53, 0.67)	0.55 (0.46, 0.64)	0.58 (0.47, 0.69)	0.49 (0.34, 0.64)	0.33 (0.13, 0.59)	0.61 (0.45, 0.7	0.83 (0.36, 1.00)
Specificity	1.00 (0.16, 1.00)	0.83 (0.69, 0.93)	0.83 (0.65, 0.94)	0.83 (0.65, 0.94)	0.76 (0.53, 0.92)	0.71 (0.42, 0.92)	0.75 (0.19, 0.9	0.00 (0.00, 0.97)
PPV_{obs}[d]	1.00 (0.83, 1.00)	0.94 (0.88, 0.97)	0.93 (0.84, 0.98)	0.91 (0.80, 0.97)	0.82 (0.63, 0.94)	0.60 (0.26, 0.88)	0.96 (0.80, 1.0	0.83 (0.36, 1.00)
NPV_{obs}[d]	0.17 (0.02, 0.48)	0.33 (0.24, 0.43)	0.32 (0.22, 0.44)	0.41 (0.29, 0.54)	0.40 (0.25, 0.57)	0.45 (0.24, 0.68)	0.16 (0.03, 0.4	0.00 (0.00, 0.97)
PPV_{50}[d]	1.00 (0.71, 1.00)	0.78 (0.68, 0.87)	0.77 (0.63, 0.87)	0.78 (0.63, 0.89)	0.67 (0.46, 0.85)	0.54 (0.21, 0.84)	0.71(0.46, 0.89	0.45 (0.10, 0.85)
NPV_{50}[d]	0.75 (0.52, 0.91)	0.68 (0.59, 0.75)	0.65 (0.55, 0.74)	0.67 (0.55, 0.77)	0.60 (0.44, 0.74)	0.52 (0.30, 0.73)	0.66(0.45, 0.83	0.00 (0.00, 1.00)

496 [a] Mass spectrometry approach taken does not discriminate between tetracycline and doxycycline.
497 [b] Concentration at or above the lowest minimal inhibitory concentration (see methods) and prior descriptions[51]
498 [c] Reference standard to define positive cholera cases is culture or qPCR (*tcpA*). Approach independent of phage exposure.
499 [d] Subscript indicates the proportion of samples that were gold-standard positive in the given group for the calculation of each predictive value, with "obs"=observed and
500 "50"=50%. For example, PPV_{50} or standardized positive predictive value indicates the positive predictive value of RDT in each group if 50% of that group was gold-
501 standard positive for cholera.
502 [e] Patients who met the following criteria had subsequent mass spectrometry: (i) culture positive for *Vc*, (ii) phage (ICP1,2,3) positive by PCR among culture-negative
503 samples, or (iii) *Vc* positive by PCR among a random 10% of samples negative by culture for *Vc* and by PCR for phage (see methods).
504
505

506 **Table S3. Among *Vc* positive samples, impact of antibiotic exposure and resistance on RDT positivity (phage removed)**[a]

Condition	RDT+	RDT- (false negatives)	OR (CI)	*P* value[b]
Ciprofloxacin (LC-MS/MS qual detection)[c]				
Exposed	30% (47)	22% (34)	0.705 (0.365-1.352)	0.3234
Not exposed	32% (49)	16% (25)		
Azithromycin (LC-MS/MS qual detection)				
Exposed	10% (15)	10% (16)	0.498 (0.223-1.105)	0.099
Not exposed	52% (81)	28% (43)		
Doxycycline (LC-MS/MS qual detection)[c]				
Exposed	12% (19)	7% (11)	1.077 (0.478-2.523)	1.000
Not exposed	50% (77)	31% (48)		
No azithromycin detected by qualitative LC-MS/MS[d]				
Isolate AZI resistant	25% (28)	14% (16)	0.750 (0.337-1.679)	0.54
Isolate AZI sensitive	43% (49)	18% (21)		
Azithromycin detected by qualitative LC-MS/MS[d]				
Isolate AZI resistant	29% (8)	21% (6)	1.333 (0.300 6.100)	1.000
Isolate AZI sensitive	25% (7)	25% (7)		

507 [a] Criteria to define cholera patients for subsequent mass spectrometry were (i) culture positive for *Vc*, (ii) phage (ICP1,2,3) positive by PCR
508 among culture-negative samples, or (iii) *Vc* positive by PCR among a random 10% of samples negative by culture for *Vc* and by PCR for
509 phage (see methods). Analyses removed samples with ICP1, 2, 3 detected. Those samples without RDT performed were excluded.
510 [b] Fisher's exact test
511 [c] Insufficient rates of resistance/sensitive strains for stratified analyses
512 [d] Among cholera patients in which the culture was positive and an isolate was obtained for AMR testing.
513

514 **Table S4. RDT performance by severity and age group with culture or qPCR (*tcpA*) as the reference standard**

	Mild (comparator)	Moderate	Severe	Moderate/Severe
0-11months				
Cases/total(%)[a]	25 / 167 (15.0)	13 / 142 (9.2)	4 / 39 (10.3)	17 / 181 (9.4)
Sensitivity	0.16 (0.05, 0.36)	0.38 (0.14, 0.68)	0.25 (0.01, 0.81)	0.35 (0.14, 0.62)
Specificity	0.73 (0.64, 0.80)	0.81 (0.73, 0.87)	0.89 (0.73, 0.97)	0.82 (0.76, 0.88)
PPV_{obs}[b]	0.09 (0.03, 0.22)	0.17 (0.06, 0.35)	0.20 (0.01, 0.72)	0.17 (0.07, 0.34)
NPV_{obs}[b]	0.83 (0.75, 0.89)	0.93 (0.86, 0.97)	0.91 (0.76, 0.98)	0.92 (0.87, 0.96)
PPV_{50}[b]	0.37 (0.21, 0.54)	0.66 (0.50, 0.80)	0.69 (0.27, 0.95)	0.67 (0.52, 0.80)
NPV_{50}[b]	0.46 (0.38, 0.55)	0.57 (0.46, 0.67)	0.54 (0.36, 0.72)	0.56 (0.47, 0.65)
1-4 years				
Cases/total(%)[a]	17 / 125 (13.6)	29 / 202 (14.4)	11 / 74 (14.9)	40 / 276 (14.5)
Sensitivity	0.06 (0.00, 0.29)	0.38 (0.21, 0.58)	0.45 (0.17, 0.77)	0.40 (0.25, 0.57)
Specificity	0.78 (0.69, 0.85)	0.82 (0.76, 0.87)	0.84 (0.73, 0.92)	0.83 (0.77, 0.87)
PPV_{obs}[b]	0.04 (0.00, 0.20)	0.26 (0.14, 0.42)	0.33 (0.12, 0.62)	0.28 (0.17, 0.42)
NPV_{obs}[b]	0.84 (0.75, 0.91)	0.89 (0.83, 0.93)	0.90 (0.79, 0.96)	0.89 (0.84, 0.93)
PPV_{50}[b]	0.21 (0.06, 0.47)	0.68 (0.54, 0.80)	0.74 (0.52, 0.90)	0.70 (0.58, 0.80)
NPV_{50}[b]	0.45 (0.36, 0.55)	0.57 (0.48, 0.65)	0.61 (0.46, 0.74)	0.58 (0.51, 0.65)
5-64 years				
Cases/total(%)[a]	32 / 97 (33.0)	185 / 797 (23.2)	118 / 351 (33.6)	303 / 1148 (26.4)
Sensitivity	0.41 (0.24, 0.59)	0.45 (0.38, 0.52)	0.67 (0.58, 0.75)	0.53 (0.48, 0.59)
Specificity	0.88 (0.77, 0.95)	0.89 (0.86, 0.91)	0.89 (0.85, 0.93)	0.89 (0.87, 0.91)
PPV_{obs}[b]	0.62 (0.38, 0.82)	0.55 (0.46, 0.63)	0.76 (0.67, 0.84)	0.63 (0.57, 0.69)
NPV_{obs}[b]	0.75 (0.64, 0.84)	0.84 (0.81, 0.87)	0.84 (0.79, 0.89)	0.84 (0.82, 0.87)
PPV_{50}[b]	0.77 (0.56, 0.91)	0.80 (0.74, 0.85)	0.86 (0.79, 0.91)	0.83 (0.79, 0.86)
NPV_{50}[b]	0.60 (0.47, 0.71)	0.62 (0.58, 0.66)	0.73 (0.67, 0.79)	0.66 (0.62, 0.69)
65+ years				
Cases/total(%)[a]	1 / 3 (33.3)	9 / 52 (17.3)	5 / 29 (17.2)	14 / 81 (17.3)
Sensitivity	1.00 (0.03, 1.00)	0.22 (0.03, 0.60)	0.40 (0.05, 0.85)	0.29 (0.08, 0.58)
Specificity	1.00 (0.16, 1.00)	0.95 (0.84, 0.99)	0.92 (0.73, 0.99)	0.94 (0.85, 0.98)
PPV_{obs}[b]	1.00 (0.03, 1.00)	0.50 (0.07, 0.93)	0.50 (0.07, 0.93)	0.50 (0.16, 0.84)
NPV_{obs}[b]	1.00 (0.16, 1.00)	0.85 (0.72, 0.94)	0.88 (0.69, 0.97)	0.86 (0.76, 0.93)
PPV_{50}[b]	1.00 (0.09, 1.00)	0.83 (0.39, 0.99)	0.83 (0.39, 0.99)	0.83 (0.54, 0.97)
NPV_{50}[b]	1.00 (0.09, 1.00)	0.55 (0.40, 0.70)	0.60 (0.38, 0.80)	0.57 (0.44, 0.69)

515 [a] Gold standard to define positive cholera cases is culture or qPCR (*tcpA*). Approach does not account for phage or antibiotics
516 exposures.
517 [b.] Subscript indicates the proportion of samples that were gold-standard positive in the given group for the calculation of each predictive value, with
518 "obs"=observed and "50"=50%. For example, PPV_{50} or standardized positive predictive value indicates the positive predictive value of RDT in each
519 group if 50% of that group was gold-standard positive for cholera.

520 **REFERENCES**

521 1. Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in
522 endemic countries. *PLoS Negl Trop Dis* 2015; **9**(6): e0003832.
523 2. Cholera Upsurge. World Health Organization (WHO). 2024.
524 https://www.who.int/emergencies/situations/cholera-upsurge (accessed Feb. 20, 2025).
525 3. Disease Outbreak News; Cholera - Global situation. World Health Organization
526 (WHO); 2023. https://www.who.int/emergencies/disease-outbreak-news/item/2023-
527 DON437 (accessed May 13, 2025).
528 4. Global deployment of rapid diagnostic tests to boost fight against cholera. World
529 Health Organization (WHO). 2024. https://www.who.int/news/item/05-04-2024-global-
530 deployment-of-rapid-diagnostic-tests-to-boost-fight-against-cholera (accessed Feb 20,
531 2025).
532 5. Hegde ST, Khan AI, Perez-Saez J, et al. Clinical surveillance systems obscure
533 the true cholera infection burden in an endemic region. *Nat Med* 2024; **30**(3): 888-95.
534 6. Xu H, Zou K, Dent J, et al. Enhanced cholera surveillance to improve vaccination
535 campaign efficiency. *Nat Med* 2024; **30**(4): 1104-10.
536 7. Nelson EJ, Harris JB, Morris JG, Jr., Calderwood SB, Camilli A. Cholera
537 transmission: the host, pathogen and bacteriophage dynamic. *Nat Rev Microbiol* 2009;
538 **7**(10): 693-702.
539 8. Nelson EJ, Chowdhury A, Flynn J, et al. Transmission of *Vibrio cholerae* is
540 antagonized by lytic phage and entry into the aquatic environment. *PLoS Pathog* 2008;
541 **4**(10): e1000187.

542 9. Nelson EJ, Grembi JA, Chao DL, et al. Gold Standard Cholera Diagnostics Are
543 Tarnished by Lytic Bacteriophage and Antibiotics. *J Clin Microbiol* 2020; **58**(9).
544 10. Madi N, Cato ET, Abu Sayeed M, et al. Phage predation, disease severity, and
545 pathogen genetic diversity in cholera patients. *Science* 2024; **384**(6693): eadj3166.
546 11. Nelson EJ, Nelson DS, Salam MA, Sack DA. Antibiotics for both moderate and
547 severe cholera. *N Engl J Med* 2011; **364**(1): 5-7.
548 12. Islam MR. Single dose tetracycline in cholera. *Gut* 1987; **28**(8): 1029-32.
549 13. Gotuzzo E, Seas C, Echevarria J, Carrillo C, Mostorino R, Ruiz R. Ciprofloxacin
550 for the treatment of cholera: a randomized, double-blind, controlled clinical trial of a
551 single daily dose in Peruvian adults. *Clin Infect Dis* 1995; **20**(6): 1485-90.
552 14. Use of antibiotics for the treatment and control of cholera. World Health
553 Organization (WHO) Global Task Force on Cholera Control (GTFCC). 2018.
554 https://www.gtfcc.org/wp-content/uploads/2019/10/gtfcc-technical-note-on-use-of-
555 antibiotics-for-the-treatment-of-cholera.pdf (accessed Feb 18, 2025).
556 15. Alexandrova L, Haque F, Rodriguez P, et al. Identification of Widespread
557 Antibiotic Exposure in Patients With Cholera Correlates With Clinically Relevant
558 Microbiota Changes. *J Infect Dis* 2019; **220**(10): 1655-66.
559 16. Saber MM, Shapiro BJ. Benchmarking bacterial genome-wide association study
560 methods using simulated genomes and phenotypes. *Microb Genom* 2020; **6**(3).
561 17. Rouard C, Collet L, Njamkepo E, et al. Long-Distance Spread of a Highly Drug-
562 Resistant Epidemic Cholera Strain. *N Engl J Med* 2024; **391**(23): 2271-3.

563 18. Lassalle F, Al-Shalali S, Al-Hakimi M, et al. Genomic epidemiology reveals
564 multidrug resistant plasmid spread between Vibrio cholerae lineages in Yemen. *Nat*
565 *Microbiol* 2023; **8**(10): 1787-98.
566 19. Seed KD, Yen M, Shapiro BJ, et al. Evolutionary consequences of intra-patient
567 phage predation on microbial populations. *Elife* 2014; **3**: e03497.
568 20. Seed KD, Bodi KL, Kropinski AM, et al. Evidence of a dominant lineage of *Vibrio*
569 *cholerae*-specific lytic bacteriophages shed by cholera patients over a 10-year period in
570 Dhaka, Bangladesh. *MBio* 2011; **2**(1): e00334-10.
571 21. Seed KD, Faruque SM, Mekalanos JJ, Calderwood SB, Qadri F, Camilli A.
572 Phase variable O antigen biosynthetic genes control expression of the major protective
573 antigen and bacteriophage receptor in *Vibrio cholerae* O1. *PLoS Pathog* 2012; **8**(9):
574 e1002917.
575 22. Yen M, Cairns LS, Camilli A. A cocktail of three virulent bacteriophages prevents
576 Vibrio cholerae infection in animal models. *Nat Commun* 2017; **8**: 14187.
577 23. Beckman DA, Waters CM. *Vibrio cholerae* phage ICP3 requires O1 antigen for
578 infection. *Infect Immun* 2023; **91**(9): e0002623.
579 24. Patel KM, Seed KD. Sporadic phage defense in epidemic *Vibrio cholerae*
580 mediated by the toxin-antitoxin system DarTG is countered by a phage-encoded
581 antitoxin mimic. *mBio* 2024; **15**(10): e0011124.
582 25. Oshiro RT, Dunham DT, Seed KD. The vibriophage-encoded inhibitor OrbA
583 abrogates BREX-mediated defense through the ATPase BrxC. *J Bacteriol* 2024;
584 **206**(11): e0020624.

585 26. LeGault K, Hays SG, Angermeyer A, et al. Temporal shifts in antibiotic resistance
586 elements govern phage-pathogen conflicts. *Science* 2021; **373**(6554):
587 2020.12.16.423150.
588 27. Seed KD, Lazinski DW, Calderwood SB, Camilli A. A bacteriophage encodes its
589 own CRISPR/Cas adaptive response to evade host innate immunity. *Nature* 2013;
590 **494**(7438): 489-91.
591 28. Brenzinger S, Airoldi M, Ogunleye AJ, Jugovic K, Amstalden MK, Brochado AR.
592 The Vibrio cholerae CBASS phage defence system modulates resistance and killing by
593 antifolate antibiotics. *Nat Microbiol* 2024; **9**(1): 251-62.
594 29. McKitterick AC, Seed KD. Anti-phage islands force their target phage to directly
595 mediate island excision and spread. *Nat Commun* 2018; **9**(1): 2348.
596 30. Jensen MA, Faruque SM, Mekalanos JJ, Levin BR. Modeling the role of
597 bacteriophage in the control of cholera outbreaks. *Proc Natl Acad Sci U S A* 2006;
598 **103**(12): 4652-7.
599 31. Faruque SM, Naser IB, Islam MJ, et al. Seasonal epidemics of cholera inversely
600 correlate with the prevalence of environmental cholera phages. *Proc Natl Acad Sci U S*
601 *A* 2005; **102**(5): 1702-7.
602 32. Faruque SM, Islam MJ, Ahmad QS, et al. Self-limiting nature of seasonal cholera
603 epidemics: Role of host-mediated amplification of phage. *Proc Natl Acad Sci U S A*
604 2005; **102**(17): 6119-24.
605 33. King AA, Ionides EL, Pascual M, Bouma MJ. Inapparent infections and cholera
606 dynamics. *Nature* 2008; **454**(7206): 877-80.

607 34. Pasricha CL, Monte AJ, Gupta SK. Season variations of cholera bacteriophage in
608 natural waters and in man in Calcutta during the year 1930. *Indian Med Gaz* 1931; **66**:
609 543-50.
610 35. Silva-Valenzuela CA, Camilli A. Niche adaptation limits bacteriophage predation
611 of Vibrio cholerae in a nutrient-poor aquatic environment. *Proc Natl Acad Sci U S A*
612 2019; **116**(5): 1627-32.
613 36. Page AL, Alberti KP, Mondonge V, Rauzier J, Quilici ML, Guerin PJ. Evaluation
614 of a rapid test for the diagnosis of cholera in the absence of a gold standard. *PLoS One*
615 2012; **7**(5): e37360.
616 37. Dick MH, Guillerm M, Moussy F, Chaignat CL. Review of two decades of cholera
617 diagnostics--how far have we really come? *PLoS Negl Trop Dis* 2012; **6**(10): e1845.
618 38. Sayeed MA, Paisie T, Alam MT, et al. Development of a Monoclonal Antibody to
619 a Vibriophage as a Proxy for Vibrio cholerae Detection. *Infect Immun* 2022; **90**(8):
620 e0016122.
621 39. Sayeed MA, Islam K, Hossain M, et al. Development of a new dipstick (Cholkit)
622 for rapid detection of Vibrio cholerae O1 in acute watery diarrhoeal stools. *PLoS Negl*
623 *Trop Dis* 2018; **12**(3): e0006286.
624 40. George CM, Rashid MU, Sack DA, et al. Evaluation of enrichment method for the
625 detection of *Vibrio cholerae* O1 using a rapid dipstick test in Bangladesh. *Trop Med Int*
626 *Health* 2014; **19**(3): 301-7.
627 41. Debes AK, Ateudjieu J, Guenou E, et al. Clinical and Environmental Surveillance
628 for Vibrio cholerae in Resource Constrained Areas: Application During a 1-Year

629 Surveillance in the Far North Region of Cameroon. *Am J Trop Med Hyg* 2016; **94**(3):
630 537-43.
631 42. Ley B, Khatib AM, Thriemer K, et al. Evaluation of a rapid dipstick (Crystal VC)
632 for the diagnosis of cholera in Zanzibar and a comparison with previous studies. *PLoS*
633 *One* 2012; **7**(5): e36930.
634 43. Gupta P, Mankere B, Chekkoora Keloth S, Tuteja U, Pandey P, Chelvam KT.
635 Increased antibiotic resistance exhibited by the biofilm of *Vibrio cholerae* O139. *J*
636 *Antimicrob Chemother* 2018; **73**(7): 1841-7.
637 44. Perez-Saez J, Bhuiyan TR, Hegde ST, et al. Rethinking cholera diagnostic test
638 performance, interpretation and evaluation: a field-based latent-class analysis in
639 Bangladesh. *medRxiv* 2024: 2024.11.19.24317512.
640 45. The treatment of diarrhoea -- A manual for physicians and other senior health
641 workers. 4th Rev. ed. Geneva, Switzerland: World Heath Organization. 2005.
642 46. Sayeed MA, Nabil IK, Bhattacharjee P, et al. Assembly and performance of a
643 cholera RDT prototype that detects both Vibrio cholerae and associated bacteriophage
644 as a proxy for pathogen detection. *J Clin Microbiol* 2025; **63**(2): e0144324.
645 47. Khan AI, Mack JA, Salimuzzaman M, et al. Electronic decision support and
646 diarrhoeal disease guideline adherence (mHDM): a cluster randomised controlled trial.
647 *Lancet Digit Health* 2020; **2**(5): e250-e8.
648 48. Khan AI, Qadri F. Epidemiology of cholera in Bangladesh: Findings from
649 Nationwide Hospital-based Surveillance, 2014-2018. *CID* 2019.

650 49. Li D, Liu CM, Luo R, Sadakane K, Lam TW. MEGAHIT: an ultra-fast single-node
651 solution for large and complex metagenomics assembly via succinct de Bruijn graph.
652 *Bioinformatics* 2015; **31**(10): 1674-6.
653 50. Manual of Clinical Microbiology. 8th ed. Washington, D.C.: American Society for
654 Microbiology Press; 2003.
655 51. Creasy-Marrazzo A, Saber MM, Kamat M, et al. Genome-wide association
656 studies reveal distinct genetic correlates and increased heritability of antimicrobial
657 resistance in *Vibrio cholerae* under anaerobic conditions. *Microb Genom* 2022; **8**(12).
658 52. Islam MT, Khan AI, Sayeed MA, et al. Field evaluation of a locally produced rapid
659 diagnostic test for early detection of cholera in Bangladesh. *PLoS Negl Trop Dis* 2019;
660 **13**(1): e0007124.
661 53. Team RC. R: A language and environment for statistical computing. R
662 Foundation for Statistical Computing. 2021. http://www.R-project.org/ (accessed May
663 26, 2019.
664 54. J L. Eulerr: Area-Proportional Euler and Venn Diagrams with Ellipses. R
665 package. 2024. https://CRAN.R-project.org/package=eulerr>.
666 55. M S, E S. EpiR: Tools for the Analysis of Epidemiological Data. R package
667 version 2.0.78. <https://CRAN.R-project.org/package=epiR> (accessed March 16,
668 2025).
669 56. Levine AC, Gainey M, Qu K, et al. A comparison of the NIRUDAK models and
670 WHO algorithm for dehydration assessment in older children and adults with acute
671 diarrhoea: a prospective, observational study. *Lancet Glob Health* 2023; **11**(11): e1725-
672 e33.